You've got it right, investors were not impressed with the last CC.

Like you, I have enough not to be hit too hard should this deteriorate to subpenny. Will hold too, for now.

That Last Shot being the major support with its only sale at CC time is something of a cold shower. For me, the abandon of purEffect for future royalties should the product become popular, was a big disappointment.

I agree, at least, the CEO is not giving false hope about OraPhyte.

Wondering how many believe the $3 million revenue predicted...

.022

go